Silexion Therapeutics Corp

Silexion Therapeutics Corp (SLXN) announced it received a notification from Nasdaq indicating a deficiency in its closing bid price, which has been below the $1.00 minimum for 30 consecutive business days. The Nasdaq hearings panel will review this deficiency to determine the company's continued listing status on the Nasdaq Capital Market. The notification does not have an immediate impact on the trading of the company's ordinary shares or warrants.

Silexion Therapeutics Corp received a delisting notice from Nasdaq due to non-compliance with the minimum shareholders' equity requirement. The company reported shareholders' equity of $44,000 for the period ended June 30, 2026, falling short of the $2,500,000 minimum. Silexion intends to appeal the decision, but faces potential trading suspension and delisting if the appeal is unsuccessful.

Silexion Therapeutics Corp announced the completion of a 1-for-10 reverse share split, effective May 28, 2026, following shareholder approval. The Company's ordinary shares began trading on a post-split adjusted basis on the Nasdaq Capital Market on May 29, 2026. Consequently, Silexion has retroactively adjusted its audited financial statements for the year ended December 31, 2025, and its unaudited interim financial statements for the quarter ended March 31, 2026, to reflect the reduced number of shares and increased per-share prices.

Silexion Therapeutics Corp. completed a public offering on August 13, 2026, raising approximately $2.5 million in gross proceeds. The offering included ordinary shares, pre-funded warrants, and Series E ordinary warrants at a purchase price of $0.65 per unit. The net proceeds of approximately $2.1 million will be allocated to advancing the company's SIL204 clinical trial and for general corporate purposes.

Silexion Therapeutics Corp. announced the pricing of a public offering of 3,846,161 ordinary shares (or equivalents) and series E warrants at a combined price of $0.65 per share. The offering is expected to generate approximately $2.5 million in gross proceeds. The company plans to use the net proceeds to advance its SIL204 clinical trial and for general corporate purposes.

Silexion Therapeutics Corp. announced a best-efforts public offering of up to 2,673,796 ordinary shares and an equal number of ordinary warrants, along with pre-funded warrants and placement agent warrants. The assumed public offering price is $1.87 per share and ordinary warrant. Concurrently, the company initiated a Phase 2/3 clinical trial for its lead product candidate, SIL204, for locally advanced pancreatic cancer in Israel and Germany. This offering aims to raise capital, following recent efforts to regain Nasdaq compliance and multiple reverse share splits.

Silexion Therapeutics Corp filed an S-1 registration statement for a public offering of ordinary shares, pre-funded warrants, and ordinary warrants. H.C. Wainwright will serve as the exclusive placement agent, receiving various fees and warrants. The offering has no minimum requirement, which could impact the total proceeds. The company recently regained compliance with Nasdaq listing standards but remains under a monitoring period. Additionally, Silexion initiated a Phase 2/3 clinical trial for its lead product candidate, SIL204, in July 2026.

Silexion Therapeutics announced new positive preclinical findings for its RNAi therapy, SIL204, demonstrating multi-mechanism immune sensitization in KRAS-driven cancers. The data showed statistically significant upregulation of FAS and downregulation of HLA-G in human KRAS-mutant pancreatic and non-small cell lung cancer cell lines. These findings, combined with previous data, support SIL204's potential as an immune sensitizer and its combination with anti-PD-(L)1 checkpoint inhibitors. Concurrently, Silexion has advanced SIL204 into Phase 2/3 clinical evaluation, with the first trial site initiated.

Silexion Therapeutics announced new positive preclinical data for SIL204, demonstrating its ability to upregulate FAS and downregulate HLA-G in human KRAS-mutant pancreatic and non-small cell lung cancer cell lines. These findings, combined with previously reported MHC-I upregulation, support a coordinated immune-sensitization effect, reinforcing the rationale for combining SIL204 with anti-PD-(L)1 checkpoint inhibitors. The company is advancing SIL204 into Phase 2/3 clinical evaluation, with the first clinical trial site initiated in July 2026.

Silexion Therapeutics Corp announced that Professor Amnon Peled resigned from its Board of Directors and all committees, including the audit committee, effective August 1, 2026, for personal reasons. Immediately following his resignation, the Board appointed Mr. Avner Lushi, an existing independent board member, to the audit committee. This appointment ensures the Company's audit committee remains in full compliance with Nasdaq listing requirements, consisting of three independent members.